TargetBeta
HHLA2
HHLA2 member of B7 family · also B7H7, B7-H5, B7y, B7-H7 · V-set domain containing
1 program in company-led studies act on HHLA2, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-B7-H7/Anti-CD3 Bispecific Antibody NPX372rule | NextPoint Therapeutics | – | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Neoplasm Metastasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 1, 2027Anti-B7-H7/Anti-CD3 Bispecific Antibody NPX372 · NextPoint Therapeutics · phase 1 · NCT07563829
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.